The political component of COVID-19 vaccine choice: Results from a conjoint experiment.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Papp Z;Papp Z; Nkansah GB; Nkansah GB
  • Source:
    Public health [Public Health] 2023 Apr; Vol. 217, pp. 33-40. Date of Electronic Publication: 2023 Jan 23.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376507 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5616 (Electronic) Linking ISSN: 00333506 NLM ISO Abbreviation: Public Health Subsets: MEDLINE
    • Publication Information:
      Publication: 2003- : Amsterdam : Elsevier
      Original Publication: London ; New York : Academic Press
    • Subject Terms:
      COVID-19*/prevention & control ; COVID-19 Vaccines* ; Politics*; Humans ; Government ; Vaccination
    • Abstract:
      Objectives: Prior research highlights the role of efficacy, vaccine safety, and availability in vaccine hesitancy. Research is needed to better understand the political driving forces behind COVID-19 vaccine uptake. We examine the effects of the origin of a vaccine, and approval status within the EU on vaccine choice. We also test if these effects differ by party affiliation among Hungarians.
      Study Design: We use a conjoint experimental design to assess multiple causal relationships. Respondents choose between two hypothetical vaccine profiles randomly generated from 10 attributes. The data were gathered from an online panel in September 2022. We applied a quota for vaccination status and party preference. Three hundred twenty-four respondents evaluated 3888 randomly generated vaccine profiles.
      Methods: We analyse the data using an OLS estimator with standard errors clustered by respondents. To further nuance our results, we test for task, profile, and treatment heterogeneity effects.
      Results: By origin, respondents prefer German (MM 0.55; 95% CI 0.52-0.58) and Hungarian (0.55; 0.52-0.59) vaccines over US (0.49; 0.45-0.52) and Chinese vaccines (0.44; 0.41-0.47). By approval status, vaccines approved by the EU (0.55, 0.52-0.57) or pending authorization (0.5, 0.48-0.53) are preferred over unauthorised ones (0.45, 0.43-0.47). Both effects are conditional on party affiliation. Government voters especially prefer Hungarian vaccines (0.6; 0.55-0.65) over others.
      Conclusions: The complexity of vaccination decisions calls for the usage of information shortcuts. Our findings demonstrate a strong political component that motivates vaccine choice. We demonstrate that politics and ideology have broken into fields of individual-level decisions such as health.
      (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
    • References:
      Hum Vaccin Immunother. 2020 Sep 1;16(9):2204-2214. (PMID: 32730103)
      Soc Sci Med. 2021 Mar;272:113642. (PMID: 33414031)
      Vaccines (Basel). 2022 May 16;10(5):. (PMID: 35632545)
      Hum Vaccin Immunother. 2021 Oct 3;17(10):3365-3370. (PMID: 34236952)
      Vaccine. 2015 Aug 14;33(34):4161-4. (PMID: 25896383)
      Expert Rev Vaccines. 2020 Oct;19(10):899-901. (PMID: 32945213)
      Nat Hum Behav. 2021 Jul;5(7):947-953. (PMID: 33972767)
      JAMA Netw Open. 2020 Oct 1;3(10):e2025594. (PMID: 33079199)
      Sci Rep. 2022 Aug 2;12(1):13293. (PMID: 35918372)
      Lancet Reg Health Eur. 2021 Feb;1:100012. (PMID: 33954296)
      Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12441-12446. (PMID: 30446611)
      BMJ Open. 2021 Jun 15;11(6):e048172. (PMID: 34130963)
      Eur J Epidemiol. 2020 Aug;35(8):775-779. (PMID: 32785815)
      Hum Vaccin Immunother. 2021 Jun 3;17(6):1612-1621. (PMID: 33242386)
      Brain Behav Immun. 2021 May;94:41-50. (PMID: 33713824)
      Hum Vaccin Immunother. 2021 Nov 2;17(11):4015-4020. (PMID: 34353226)
      Vaccine. 2014 Nov 20;32(49):6649-54. (PMID: 25280436)
      Lancet. 2022 Feb 19;399(10326):699-701. (PMID: 35123665)
      Expert Rev Vaccines. 2021 Aug;20(8):921-933. (PMID: 34252336)
      PLoS One. 2022 May 4;17(5):e0266003. (PMID: 35507554)
      Nat Med. 2021 Aug;27(8):1338-1339. (PMID: 34272500)
      Vaccines (Basel). 2021 Mar 22;9(3):. (PMID: 33810131)
      PLoS One. 2018 Jan 25;13(1):e0191728. (PMID: 29370265)
      J Health Commun. 2022 Jun 3;27(6):416-426. (PMID: 36069353)
      J Health Commun. 2020 Oct 2;25(10):799-807. (PMID: 33719881)
      Hum Vaccin Immunother. 2021 Dec 2;17(12):4982-4992. (PMID: 34614385)
      Lancet. 2020 Sep 26;396(10255):898-908. (PMID: 32919524)
      Vaccines (Basel). 2021 Jan 12;9(1):. (PMID: 33445581)
      Soc Sci Med. 2022 Oct;310:115278. (PMID: 35994879)
      Soc Sci Med. 2021 Mar;272:113638. (PMID: 33414032)
      J Behav Med. 2023 Apr;46(1-2):185-200. (PMID: 35567729)
      Hum Vaccin Immunother. 2022 Dec 31;18(1):1950504. (PMID: 34325612)
      PLoS One. 2021 Apr 16;16(4):e0250123. (PMID: 33861765)
      Lancet Public Health. 2021 Apr;6(4):e210-e221. (PMID: 33556325)
      Public Health. 2021 May;194:245-251. (PMID: 33965796)
      Hum Vaccin Immunother. 2021 Oct 3;17(10):3495-3499. (PMID: 34191680)
    • Contributed Indexing:
      Keywords: COVID-19 vaccines; SARS-CoV-2; Vaccination
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20230227 Date Completed: 20230403 Latest Revision: 20230412
    • Publication Date:
      20240628
    • Accession Number:
      PMC9868381
    • Accession Number:
      10.1016/j.puhe.2023.01.014
    • Accession Number:
      36848795